Modeling the relationship between drug lipophilicity and potential for an interaction with orlistat

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 595-599

  Zhi, Jianguo ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

drug interaction; lipophilicity; Orlistat

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; AMITRIPTYLINE; ASTEMIZOLE; ATORVASTATIN; ATOVAQUONE; BETA CAROTENE; BEZAFIBRATE; CYCLOSPORIN; DESOGESTREL; DIGOXIN; ETHINYLESTRADIOL; FLUOXETINE; GLIBENCLAMIDE; ISOTRETINOIN; LOSARTAN; METFORMIN; NIFEDIPINE; NORTRIPTYLINE; PHENTERMINE; PHENYTOIN; PHYTOMENADIONE; PRAVASTATIN; RETINOL ACETATE; RETINOL PALMITATE; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; HYDROPHOBICITY; LIPOPHILICITY; MODEL; RECOMMENDED DRUG DOSE;

ANTI-OBESITY AGENTS; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LACTONES; MALE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 84859064590     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011398363     Document Type: Article

References (17)

1. Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol. 1995;35:840-843.
2. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol. 1996;36:654-658. (Pubitemid 26260547)
3. Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1996;36:659-666. (Pubitemid 26262056)
4. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol. 1996;36:352-355. (Pubitemid 26125955)
5. Zhi J, Moore R, Kanitra L, Mulligan TE. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol. 2002;42:1011-1019. (Pubitemid 34920799)
6. Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, alipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003;43:428-435. (Pubitemid 36368785)
7. Oo C, Akbari B, Lee S, et al. Effect of orlistat, anovel antiobesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia. Clin Drug Invest. 1999;17:217-223. (Pubitemid 29145735)
8. Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol. 1995;35:521-525.
9. Hartmann D, Guzelhan C, Zuiderwijk PB, Odink J. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol. 1996;50:421-424. (Pubitemid 26228259)
10. Zhi J, Melia AT, Koss-Twardy SG, Arora S, Patel IH. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of â-carotene in healthy volunteers. J Clin Pharmacol. 1996;36:152-159. (Pubitemid 26082401)
11. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996;36:647-653. (Pubitemid 26260546)
12. Goldman P. Olestra: assessing its potential to interact with drugs in the gastrointestinal tract. Clin Pharmacol Ther. 1997;61: 613-618. (Pubitemid 27279922)
13. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH. Retrospective population-based analysis of the doseresponse (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56:82-85. (Pubitemid 24251568)
14. Hilger E, Quiner S, Ginzel I, Walter H, Saria L, Barnas C. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol. 2002;22:68-70. (Pubitemid 34101295)
15. Pyka A, Babuska M, Zachariasz M. A comparison of theoretical methods of calculation of partition coefficients for selected drugs. Acta Pol Pharm. 2006;63:159-167. (Pubitemid 351359750)
16. Joshi HN, Fakes MG, Serajuddin ATM. Differentiation of 3:hydroxy-3-methylglutaryl-coenzyme Areductase inhibitors by their relative lipophilicity. Pharm Pharmacol Commun. 1999;5:269-271. (Pubitemid 29245825)
17. Mück W, Adelmann H-G, Ruf T, et al. Lack of pharmacokinetic drug-drug interaction between orlistat and cerivastatin. Clin Drug Invest. 2000;19:71-73. (Pubitemid 30071991)